IL269357B2 - A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer - Google Patents
A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancerInfo
- Publication number
- IL269357B2 IL269357B2 IL269357A IL26935719A IL269357B2 IL 269357 B2 IL269357 B2 IL 269357B2 IL 269357 A IL269357 A IL 269357A IL 26935719 A IL26935719 A IL 26935719A IL 269357 B2 IL269357 B2 IL 269357B2
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- amino
- pyridin
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472345P | 2017-03-16 | 2017-03-16 | |
| PCT/US2018/022961 WO2018170447A1 (en) | 2017-03-16 | 2018-03-16 | Combination therapies for the treatment of breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL269357A IL269357A (en) | 2019-11-28 |
| IL269357B1 IL269357B1 (en) | 2024-06-01 |
| IL269357B2 true IL269357B2 (en) | 2024-10-01 |
Family
ID=61874039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL269357A IL269357B2 (en) | 2017-03-16 | 2018-03-16 | A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11083722B2 (https=) |
| EP (2) | EP3595725B1 (https=) |
| JP (1) | JP7219224B2 (https=) |
| KR (1) | KR102517650B1 (https=) |
| CN (1) | CN110636862B (https=) |
| AU (1) | AU2018234903B2 (https=) |
| BR (1) | BR112019019261A2 (https=) |
| CA (1) | CA3056701A1 (https=) |
| IL (1) | IL269357B2 (https=) |
| MA (1) | MA47776A (https=) |
| MX (1) | MX2019010981A (https=) |
| RU (1) | RU2764724C2 (https=) |
| SG (1) | SG11201908531WA (https=) |
| WO (1) | WO2018170447A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041986A1 (en) * | 2016-11-28 | 2018-05-31 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
| MX2020007312A (es) | 2018-01-08 | 2021-01-08 | G1 Therapeutics Inc | Regimenes de dosificacion superior de g1t38. |
| JP2023548340A (ja) * | 2020-11-06 | 2023-11-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳癌の治療方法 |
| CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2483736A (en) * | 2010-09-16 | 2012-03-21 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and use thereof |
| US20160347717A1 (en) * | 2015-05-29 | 2016-12-01 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| DE19959546A1 (de) | 1999-12-09 | 2001-06-21 | Rhone Poulenc Rorer Gmbh | Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen |
| CA2397593C (en) | 2000-01-18 | 2009-11-10 | Aventis Pharmaceuticals Inc. | Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one |
| ATE284400T1 (de) | 2000-01-18 | 2004-12-15 | Aventis Pharma Inc | Ethanolsolvat von (-)-cis-2-(2-chlorphenyl)-5,7- dihydroxy-8- (4r-(3s-hydroxy-1- methyl)piperidinyl)-4h-1-benzopyran-4-on |
| WO2002022133A1 (en) | 2000-09-12 | 2002-03-21 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| ES2251677T3 (es) | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| KR20070107707A (ko) | 2005-01-21 | 2007-11-07 | 아스텍스 테라퓨틱스 리미티드 | 피라졸 키나제 억제제와 추가 항종양제의 조합물 |
| JP5475234B2 (ja) | 2005-01-21 | 2014-04-16 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
| MX2007008781A (es) | 2005-01-21 | 2007-09-11 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| JP2008255008A (ja) | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| US7776832B2 (en) | 2006-04-21 | 2010-08-17 | Gem Pharmaceuticals, Llc | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| WO2008001101A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008007122A2 (en) | 2006-07-14 | 2008-01-17 | Astex Therapeutics Limited | Combinations of pyrazole derivatives for the inhibition of cdks and gsk's |
| EP2049106A2 (en) | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008009954A1 (en) | 2006-07-21 | 2008-01-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| WO2011130232A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| KR102051881B1 (ko) | 2010-10-25 | 2019-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| CN103703000B (zh) | 2011-03-23 | 2015-11-25 | 安姆根有限公司 | Cdk4/6和flt3的稠合三环双重抑制剂 |
| AU2013352406A1 (en) | 2012-11-28 | 2015-06-04 | Novartis Ag | Combination therapy |
| DK2968290T3 (da) | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| KR102529049B1 (ko) * | 2013-08-14 | 2023-05-08 | 노파르티스 아게 | 암의 치료를 위한 조합 요법 |
| JP2017507964A (ja) | 2014-03-13 | 2017-03-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターを用いた治療的組合せ |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN104529904B (zh) | 2015-01-09 | 2016-08-31 | 苏州明锐医药科技有限公司 | 玻玛西尼的制备方法 |
| WO2016126889A1 (en) | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| JP7019422B2 (ja) * | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ，インコーポレイテッド | 癌を治療するための方法 |
-
2018
- 2018-03-16 US US16/493,931 patent/US11083722B2/en active Active
- 2018-03-16 RU RU2019132893A patent/RU2764724C2/ru active
- 2018-03-16 EP EP18715441.4A patent/EP3595725B1/en active Active
- 2018-03-16 CA CA3056701A patent/CA3056701A1/en active Pending
- 2018-03-16 SG SG11201908531W patent/SG11201908531WA/en unknown
- 2018-03-16 KR KR1020197029851A patent/KR102517650B1/ko active Active
- 2018-03-16 WO PCT/US2018/022961 patent/WO2018170447A1/en not_active Ceased
- 2018-03-16 BR BR112019019261-1A patent/BR112019019261A2/pt not_active Application Discontinuation
- 2018-03-16 JP JP2019550800A patent/JP7219224B2/ja active Active
- 2018-03-16 MX MX2019010981A patent/MX2019010981A/es unknown
- 2018-03-16 IL IL269357A patent/IL269357B2/en unknown
- 2018-03-16 MA MA047776A patent/MA47776A/fr unknown
- 2018-03-16 AU AU2018234903A patent/AU2018234903B2/en active Active
- 2018-03-16 EP EP23159590.1A patent/EP4218820A3/en not_active Withdrawn
- 2018-03-16 CN CN201880030008.9A patent/CN110636862B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2483736A (en) * | 2010-09-16 | 2012-03-21 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and use thereof |
| US20160347717A1 (en) * | 2015-05-29 | 2016-12-01 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4218820A3 (en) | 2023-09-20 |
| IL269357B1 (en) | 2024-06-01 |
| EP3595725A1 (en) | 2020-01-22 |
| JP7219224B2 (ja) | 2023-02-07 |
| BR112019019261A2 (pt) | 2020-06-16 |
| SG11201908531WA (en) | 2019-10-30 |
| KR102517650B1 (ko) | 2023-04-05 |
| EP3595725B1 (en) | 2023-05-03 |
| MA47776A (fr) | 2020-01-22 |
| MX2019010981A (es) | 2020-09-07 |
| EP4218820A2 (en) | 2023-08-02 |
| CN110636862B (zh) | 2026-03-20 |
| AU2018234903B2 (en) | 2024-02-08 |
| CN110636862A (zh) | 2019-12-31 |
| IL269357A (en) | 2019-11-28 |
| KR20190125448A (ko) | 2019-11-06 |
| WO2018170447A1 (en) | 2018-09-20 |
| CA3056701A1 (en) | 2018-09-20 |
| JP2020510075A (ja) | 2020-04-02 |
| RU2764724C2 (ru) | 2022-01-19 |
| US20210113537A1 (en) | 2021-04-22 |
| RU2019132893A3 (https=) | 2021-06-24 |
| RU2019132893A (ru) | 2021-04-16 |
| AU2018234903A1 (en) | 2019-10-10 |
| US11083722B2 (en) | 2021-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11083722B2 (en) | Combination therapies for the treatment of breast cancer | |
| CA3034875C (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| JP7665700B2 (ja) | 肝細胞癌の治療のための併用療法 | |
| EP4203963A1 (en) | Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma | |
| US11357769B2 (en) | Drug combinations for reducing cell viability and/or cell proliferation | |
| WO2024081948A1 (en) | Combination for use in treating cancers | |
| RU2787993C2 (ru) | Комбинированные терапии для лечения гепатоцеллюлярной карциномы | |
| TW202416992A (zh) | 雌激素受體降解劑之給藥方案 |